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Abstract
Background: Cervical cancer is caused by high-risk types of human papillomavirus (HPV). DNA testing of such
high-risk types of HPV could improve cervical screening.The aim of the study was to compare the sensitivities and
positive predictive values of two commercially available typing assays (Qiagen LQ and Roche LA) and to
comparatively assess the distribution of HPV types with these two assays.
Methods: The study population comprised 311 ASCUS + women with abnormal pap tests who were HCII positive
and who were admitted to three European referral gynecology clinics between 2007 and 2010 (Madrid, Marseille
and Milan). All patients underwent LQ and LA tests.
Results: The sensitivity of the two assays for HPV typing was 94% for LQ and 99% for LA (compared with HCII). The
overall concordance between LQ and LA was 93%. The three prevalent genotypes, HPV16, HPV18, and HPV31, were
identified with a high concordance using the two assays: kappa 0.93, 0.83, and 0.91, respectively. Mixed genotypes
were more frequently detected by LA than by LQ: 52% vs. 18%, respectively (p < .0001).
Conclusions: These assays have a good clinical sensitivity for detecting HPV types in CIN2+ patients and allow the
virus type to be detected in the same experiment. Our study revealed no significant difference between LQ and LA
for CIN2+ or CIN3+ diagnosis, indicating similar distributions of HPV types and a mixed genotype detection that is
higher for LA than for LQ.
Background
Cervical cancer is caused by high-risk types of human
papillomavirus (HPV). DNA testing of such high-risk
(HR) types of HPV could improve cervical screening [1-3].
It has been demonstrated that either HPV HR type 16 or
type 18 has a high CIN2+ predictive value [4-6]. The US
guidelines suggest that if an FDA-approved genotyping test
were available, it would be reasonable to use it in women
30 years old and older with negative cytology results and
positive HPV tests. The detection of HPV 16 and/or 18 in
that setting would be an indication for referral to col-
poscopy [7]. In this context, the Linear Array HPV (LA)
(Roche) Genotyping Test, which detects 37 HPV geno-
types by reverse line blot (RLB) hybridization, correlates
in performance to the HPV HCII test for detection of
CIN2+ [8-12]. Tools based on different technologies
(reverse dot blot: LA, Roche; DNA-chip: Papillocheck®
HPV-screening, Greiner; clinical arrays: CLART® Genomica)
serve to assess the distribution of the HPV genotypes
[13,14]. A novel commercial test (Qiagen LQ®) for the
identification of 18 HR-HPV types on GP5+/6 + −PCR
products was developed and has been analytically com-
pared to the established RLB genotyping assay [15].
Godinez et al. recently performed clinical validation of
LQ in women >40 years old [16]. However, no clinical
validation has been performed in women aged >18 years
old with an abnormal pap test.The primary aim of our
study was to compare the sensitivities and positive pre-
dictive values of two commercially available typing assays
(LQ and LA) comparatively with HCII using CIN2+ as the
clinical cut-off. The secondary aim was to comparatively
assess the distribution of HPV types with these two assays.
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The study population comprised 311 ASCUS + women
who were admitted to three European referral gynecology
clinics between 2007 and 2010: 158 patients from Madrid
(Spain), 58 from Marseille (France), and 95 from Milan
(Italy). The criteria for eligibility were abnormal cervical
smears, HCII-positive result, and referred for colposcopy
with histology. A colposcopy, histology, and HCII test
were performed independently at each study center
(i.e., Madrid, Marseille, and Milan). Before colposcopy, a
cervical sample was obtained using the ThinPrep method
(Cytyc France Sarl, Roissy, France). The cervical scrapes
were collected with the PreservCyt transport medium
(Cytyc Corp., Marlborough, MA) and sent to a reference
laboratory (Laboratoire Alphabio, Marseille, FRANCE),
where the LQ and LA HPV tests were performed. All
these tests were performed on the samples collected
in PreservCyt liquid media for liquid-based cytology
(ThinPrep). Informed consent was obtained from each
participant according to ethics committee guidelines.
This study was approved by the CPP Sud-Med I
(Comité de Protection des Personnes Sud Méditerranée I)
under the reference number 07 22.
Hybrid capture II (HCII) (Digene)
This assay detects 13 HR-HPV genotypes (HPV16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). The HCII test
was performed using the automated HCII assay system as
previously described (13). Samples with an RLU/CO
value ≥1 were considered HCII-HR positive. Samples with
an RLU/CO value <1.0 were considered HCII-HR negative.
Qiagen HPV genotyping LQ test analysis
The LQ test utilizes probes for 18 HR-HPV types (i.e., HPV
16,18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73,
and 82) that are linked to color-coded micro-beads [16,17].
The LQ test detection kit procedure was performed in a
Luminex 100 IS System (Luminex Corporation), according
to the manufacturer’s instructions [18].
Roche LA
This assay detects 37 HR and low-risk (LR) genotypes indi-
vidually. They include 15 HR-HPV genotypes (HPV16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), 3 prob-
able HR-HPV genotypes (HPV26, 53, 66), 10 LR-HPV geno-
types (HPV6, 11, 40, 42, 54, 61, 70, 72, 81, and CP6108), and
9 genotypes for which the risk is still undetermined (HPV55,
62, 64, 67, 69, 71, 83, 84, and IS39) [9]. The LA test was
performed according to the manufacturer’s instructions.
In-house real-time PCR high-risk HPV genotyping
An in-house Real Time (RT)-PCR genotyping method
was performed on LA and LQ discordant cases. All PCR
reactions were performed in a 20-μL volume using an
ABI PRISM 7000 (Applied Biosystems). Each individual
reaction contained 10 μL of Platinum® Quantitative PCR
SuperMix-UDG with ROX (Invitrogen, ref 11743), 5 μL
of 0.4 μM primers + probes mix (MWG) and up to 5 μL
of HPV DNA or sterile DNAse/RNAse-free grade water
in non-template controls. The amplification profile was
initiated by a 2-minute incubation at 50°C, followed by
a 15-minute incubation at 95°C, and a two-step amplifi-
cation of 15 seconds at 95°C and 60 seconds at 60°C for
45 cycles. For each 96-well PCR microplate, six patients
could be tested for the 12 HPV HR (one HPV/well), the
HBB gene, and a negative control. To optimize the re-
producibility of the test, filling of the plates was con-
ducted using a TECAN Freedom EVO 75 robot. Data
were collected during the amplification step using ABI
Prism 7000 SDS Software (Applied Biosystem).
In-house real-time PCR detects 12 HR-HPV genotypes:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. To validate
the performance of our in-house qualitative HPV type de-
tection method using real-time PCR, standard curves were
obtained by the amplification of a dilution series of ten
million to ten copies obtained from CaSki cell lines for
HPV 16, HPV DNA called HPV 475 (sample previously
analyzed, infected with HPV18) and DNA extracted from
PBMC as a positive control for HBB.
Statistical analyses
Two-sided P values were calculated by Chi-square or
Fisher exact tests and placed on 2 × 2 contingency tables.
Kappa statistics were used for the measuring concordance
between LQ and LA. The Kappa statistics values range
from 0 to 1 (<0.20, poor; 0.21-0.40, weak; 0.41-0.60,
moderate; 0.61-0.80, good; and 0.81-1.00, very good)
[19]. All P values <0.05 were considered significant.
Calculations were performed using SAS software (SAS
V9.1, SAS Institute Inc., Cary, NC).
Results
The key characteristics of the 311 patients are shown in
Table 1. The median age was 36 [min 18 – max 79] years;
and 142 (46%) patients were at least CIN2. In addition,
129 (41%) patients were CIN1, and 40 (13%) had a normal
biopsy. HR-HPV types were detected in 287 (92%) cases
with LQ, and in 307 (99%) cases with LA.
Sensitivities, specificities, positive and negative predictive
values are reported in Table 2. Both tests displayed good
sensitivity (LQ 94% and LA 99%). None of the comparisons
of sensitivities and NPVs displayed statistically relevant
differences between tests.
Only HPV genotypes common to LQ and LA were con-
sidered in the following analysis. Thus, HR-HPV detection
was 95% for LQ and 99% for LA. Mixed HPV genotypes
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were more frequently detected by LA: 52% vs. 18%, re-
spectively, p < .0001.
Figures 1A and 1B show the absolute risk of CIN2+ or
CIN3+ according to the presence of HPV16, HPV18,
HPV31, or other HR-HPV types. HR-HPV types 16, 18,
and 31 were chosen because of their high level of onco-
genicity and for their high prevalence. The absolute risk
of CIN2+ when typed with HPV16 by LQ was 60%,
which is similar to the LA risk (61%). When typed with
HPV18, the absolute risk of CIN2+ was 28% for both LQ
and LA (Figure 1A). Similarly, the absolute risk of CIN3+
when typed HPV16 by LQ was 23%, which is similar to
the LA risk (25%). When typed HPV18, the absolute risk
of CIN3+ was 6% for both LQ and LA (Figure 1B).
The two tests displayed a high overall concordance rate
of 93%. Among the 311 samples, 286 (92%) were HR-HPV
positive by both tests, 3 (1%) were HR-HPV negative by
both tests, and 22 (7%) were discordant. Among the 21
discordant cases HR-HPV negative by LQ, and seven
were CIN2+ based on biopsy. The case that was HR-HPV
negative by LA was CIN1 in biopsy. The in-house RT-PCR
test was performed on LA and LQ discordant cases
(Table 3). Among the 22 discordant cases, 21 were HR-
HPV positive by LA, and one was HR-HPV positive by
LQ. In-house RT-PCR was in accordance with LA in
nine cases and in accordance with LQ in 13 cases.
Table 4 shows the concordance between LQ and LA
according to HPV genotype. The two tests are concordant
for the majority of HPV genotypes except for HPV35
(Kappa = 0.41, p = 0.002), HPV53 (Kappa = 0.36, p < .001),
HPV59 (Kappa = 0.29, p = 0.02), HPV73 (Kappa = 0.30,
p = 0.04), and mixed genotypes (Kappa = −0.08, p < .001).
LA detected HPV35 in 11 cases, but the Qiagen assay did
not detect HPV35. Among these 11 cases, only two cases
were HPV negative by LQ. In the nine remaining cases,
LQ detected other HR HPV types. In the same manner,
LA detected HPV53 in 35 cases and LQ in eight cases. All
eight cases detected HPV53 by LQ were also detected to
have HPV53 by LA. LA detected HPV59 in 18 cases. LQ
detected HPV59 in three cases, and all were detected by
LA. Among the 18 cases with detected HPV59 by LA, five
were HPV negative by LQ. HPV73 was the last HPV
Table 1 Key characteristics of the study population
Characteristics ASCUS + patients (N = 311)
Age; median [min-max] 36 [18–79]











Qiagen HPV LQ – N (%)
Positive (all types) 287 (92)
Negative 24 (8)
Roche LA – N (%)
Positive (all types) 307 (99)
Negative 4 (1)
Table 2 Test performance for CIN2+ histology detection









HPV HR Negative 16 8 94 9 46 67
HPV HR Positive 154 133
Roche LA
HPV HR Negative 3 1 99 2 46 75
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LQ LAA: CIN2+
Figure 1 Absolute risks of CIN2+ (A) and CIN3+ (B) according
to HPV 16, HPV 18, HPV 31, or other HPV types.
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type for which discrepancies between LA and LQ were
significant. LA detected HPV73 in 10 cases and LQ in
three cases. Among the three LQ HPV73 cases, one was
not detected as HPV73 by LA.
Discussion
In this study, an LQ HPV genotyping test was compared
to the widely used LA test. LQ and LA were similar in
HR-HPV detection (92% of concordant HR-HPV positive
results). Although all samples were HCII positive, HPV
negative results using the LA assay were found in 4 (1%)
cases, compared with 24 (8%) for the LQ assay. Among the
311 samples, 286 (92%) were HR-HPV positive by both
assays, 3 (1%) were HR-HPV negative by both assays,
and 22 (7%) were discordant. Among the 22 LA and LQ
discordant cases, in-house RT-PCR was in accordance
with LA in nine cases and with LQ in 13 cases. A reason
for the discordance between LA and LQ might be that
among the 21 HPV-positive cases detected by LA but
not by LQ, there were nine cases in which LA detected
HR-HPV types LQ was not designed to detect.
The LA and LQ tests were concordant in detecting the
majority of HR-HPV genotypes except HPV35, HPV53,
HPV59, and HPV73. The three prevalent genotypes,
HPV16, HPV18, and HPV31, were found with a high con-
cordance between LA and LQ: kappa 0.93, 0.83, and 0.91,
respectively. These findings corroborate those reported by
Godinez et al. [16]. All the cases where the listed HPV
types were detected by LQ (35, 53, 59, and 73) were also
detected by LA, except for one case where LQ detected
HPV73 but not LA. Godinez et al. reported overestimation
of LA for HPV52 and HPV53 because of cross-reactivity
with other probes. We think it might explain the discrepan-
cies between LA and LQ in detecting HPV35, HPV53,
HPV59, and HPV73 [16]. Mixed genotypes were more fre-
quently detected by LA than LQ: 52% vs. 18%, respectively
(p < .0001). As previously reported, LA is known to have a
higher power in identifying mixed genotypes, but the clin-
ical implication of this higher power is not well established
[8,9,16]. One hypothesis could be that the genotyping re-
sults are due to the nature of the genotype detection used
by the test: LA uses a strip that is known to be more sensi-
tive to detect a small quantity of DNA, instead of the liquid
used with the LQ.
The analysis of absolute risk of CIN2+ and CIN3 revealed
no difference between LA and LQ. The two assays are
very similar, regardless of HPV type. As an example, the
Table 3 Interpretation of the 22 LA/LQ discordant cases
using the in house RT-PCR assay






In house RT-PCR in
accordance with:
DISC1 35 Negative 35 Roche LA
DISC2 35.51.52 Negative 35.51 Roche LA
DISC3 39.54 Negative 39 Roche LA
DISC4 42 Negative Negative Qiagen LQ
DISC5 51 Negative Negative Qiagen LQ
DISC6 51.81 Negative 51 Roche LA
DISC7 53 Negative Negative Qiagen LQ
DISC8 53.59 Negative Negative Qiagen LQ
DISC9 54.42 Negative Negative Qiagen LQ
DISC10 54.84 Negative Negative Qiagen LQ
DISC11 59 Negative 59 Roche LA
DISC12 59 Negative 59 Roche LA
DISC13 59.61 Negative 59 Roche LA
DISC14 59.61.81 Negative 59 Roche LA
DISC15 6.84.42 Negative Negative Qiagen LQ
DISC16 61 Negative Negative Qiagen LQ
DISC17 67 Negative Negative Qiagen LQ
DISC18 67 Negative Negative Qiagen LQ
DISC19 67 Negative Negative Qiagen LQ
DISC20 68 Negative Negative Qiagen LQ
DISC21 81 Negative 56 Roche LA
DISC22 Negative 68 68 Qiagen LQ






Kappa* [95% CI] p-value**
HPV 16 128 131 0.93 [0.89-0.97] 0.60
HPV 18 14 18 0.83 [0.69-0.98] 0.87
HPV 26” 1 1 1.00 [1.00-1.00] 1.00
HPV 31 50 50 0.91 [0.84-0.97] 0.50
HPV 33 26 19 0.83 [0.71-0.95] 0.16
HPV 35 15 4 0.41 [0.13-0.69] 0.002
HPV 39 12 9 0.85 [0.69-1.00] 0.25
HPV 45 14 11 0.88 [0.74-1.00] 0.27
HPV 51 22 14 0.77 [0.61-0.92] 0.15
HPV 52 17 14 0.42 [0.20-0.65] 0.50
HPV 53 35 8 0.35 [0.17-0.52] <.0001
HPV 56 21 21 0.85 [0.73-0.97] 0.50
HPV 58 27 18 0.79 [0.65-0.92] 0.08
HPV 59 18 3 0.27 [0.03-0.52] 0.02
HPV 66 18 14 0.74 [0.56-0.91] 0.29
HPV 68 8 9 0.58 [0.29-0.86] 0.05
HPV 73 10 3 0.30 [0.00-0.62] 0.04
HPV 82‴ 1 1 1.00 [1.00-1.00] 1.00
Mixed 163 56 −0.08 [−0.15-0.02] <.0001
*: Kappa statistic (<.20, poor; 0.21-0.40, weak; 0.41-0.60, moderate; 0.61-0.80,
good; 0.81-1.00, very good). ** Measures significance of the difference
between LQ and LA. ″: Sample positive for HPV 26 was the same for LQ and
LA. ‴: Sample positive for HPV 82 was the same for LQ and LA.
Halfon et al. BMC Infectious Diseases 2013, 13:499 Page 4 of 6
http://www.biomedcentral.com/1471-2334/13/499
absolute risk of CIN2+ when HPV16 positive (60%) is
approximately two-fold the absolute risk of CIN2+ when
HPV18 positive (28%).
The overall agreements between LA and LQ genotyping
assays indicated highly similar outcomes and were close to
those in recent reports using different genotyping methods
[8,9,20-23]. However, the HR-HPV positivity rate was higher
(not statistically) with the LA assay than with the LQ.
Genotype-specific results obtained with LA and LQ
were highly similar, with 91% of concordant or com-
patible results.
Regarding the laboratory technical characteristics, LQ®
uses multiplex, bead-based xMAP technology and an auto-
mated, high-throughput read-out with either the LiquiChip
200 workstation (QIAGEN, Hilden, Germany) or Luminex
100 IS System (Luminex Corporation, Austin, TX).
The test was developed for identification of the 18 HR-
HPV genotypes associated with cervical cancer by
using GP5+/6 + −PCR products. A high level of agree-
ment has been reported between the LQ test and the
LA assay for detection and genotyping of 18 HR-HPV
types in HCII positive specimens [15].
A limitation of this study might be its relative low
number of patients included despite the specific inclu-
sion criteria.
Conclusions
In conclusion, LQ and LA assays both have good clinical
sensitivity for detecting HPV types in CIN2+ adult
women. This study revealed no significant difference be-
tween LQ and LA for CIN2+ or CIN3+ diagnosis, in
addition to indicating similar distributions of HPV types.
These assays detect and determine the type of virus in
the same experiment. The availability of HPV genotyping
methods with demonstrated reliable clinical performance
is a necessary prerequisite for HPV genotyping assays.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PH conceived the study, participated in its design and coordination,
recruited patients, and drafted the manuscript. MTS, MS, and MLML
participated in the design of the study and coordination, recruited patients,
and helped to draft the manuscript. AR, SR, HK, and CC performed the
sample analyses. GP performed the statistical analyses and drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
The authors would like to acknowledge Qiagen for providing reagents to
perform the study.
Author details
1Laboratoire Alphabio, 1 rue Melchior Guinot, Marseille 13003, France.
2Hôpital Européen, Marseille, France. 3Unità Medicina di Laboratorio
Laboratory Medicine Unit Milano, Milan, Italy. 4CDL Pharma, Marseille, France.
5Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, Spain.
Received: 13 March 2013 Accepted: 17 October 2013
Published: 24 October 2013
References
1. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG,
Mielzynska-Lohnas I, Rush BB, Schiffman M: Baseline cytology, human
papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort
analysis. J Natl Cancer Inst 2003, 95(1):46–52.
2. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner
J, Meijer CJ: Overview of human papillomavirus-based and other novel
options for cervical cancer screening in developed and developing
countries. Vaccine 2008, 26(Suppl 10):K29–K41.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders
PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types
associated with cervical cancer. N Engl J Med 2003, 348(6):518–527.
4. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB,
Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer
and cancer in women with human papillomavirus (HPV) type 16 or 18
and the possible utility of type-specific HPV testing in clinical practice.
J Natl Cancer Inst 2005, 97(14):1072–1079.
5. Woodman CB, Collins SI, Young LS: The natural history of cervical HPV
infection: unresolved issues. Nat Rev Cancer 2007, 7(1):11–22.
6. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2002, 2(5):342–350.
7. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006
consensus guidelines for the management of women with abnormal
cervical cancer screening tests. Am J Obstet Gynecol 2007, 197(4):346–355.
8. Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, Syrjanen
K: Detection of human papillomavirus genotypes among high-risk
women: a comparison of hybrid capture and linear array tests. Sex
Transm Dis 2008, 35(5):521–527.
9. Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT:
Comparison of the clinical performance of carcinogenic HPV typing of
the Linear Array and Papillocheck HPV-screening assay. J Clin Virol 2010,
47(1):38–42.
10. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B:
Relevance of HPV mRNA detection in a population of ASCUS plus women
using the NucliSENS EasyQ((R)) HPV assay. J Clin Virol 2010, 47(2):177–181.
11. Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc B:
Evaluation of the clinical performance of the Abbott RealTime high-risk
HPV for carcinogenic HPV detection. J Clin Virol 2010, 48(4):246–250.
12. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL: High-risk
human papillomavirus testing in women with ASC-US cytology: results
from the ATHENA HPV study. Am J Clin Pathol 2011, 135(3):468–475.
13. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina
R, McCarthy J, Buckley H, et al: Comparison of predictors for high-grade
cervical intraepithelial neoplasia in women with abnormal smears.
Cancer Epidemiol Biomarkers Prev 2008, 17(11):3033–3042.
14. Halfon P, Benmoura D, Agostini A, Khiri H, Penaranda G, Martineau A, Blanc
B: Stepwise algorithm combining HPV high-risk DNA-based assays and
RNA-based assay for high grade CIN in women with abnormal smears
referred to colposcopy. Cancer Biomark 2010, 7(3):133–139.
15. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer
CJ, van Doorn LJ, Quint WG: High-throughput genotyping of high-risk HPV
by the digene HPV Genotyping LQ Test using GP5+/6 + −PCR and xMAP
technology. J Clin Virol 2009, 46(Suppl 3):S21–S26.
16. Godinez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo
IG, Bosch FX, de Sanjose S: Performance of the digene LQ, RH and PS
HPVs genotyping systems on clinical samples and comparison with HC2
and PCR-based Linear Array. Infect Agent Cancer 2011, 6:23.
17. Halfon P, Lindemann ML, Raimondo A, Ravet S, Camus C, Khiri H, Penaranda
G, Sideri M, Sandri MT: HPV genotype distribution according to severity of
cervical neoplasia using the digene HPV genotyping LQ test. Arch Virol
2013, 158(6):1143–1149.
18. Qiagen: LiquiChip applications handbook: for protein-based suspension arrays
using xMAP technology. Qiagen; 2006.
19. Landis JR, Koch GG: The measurement of observer agreement for
categorical data. Biometrics 1977, 33(1):159–174.
20. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ:
Cross-sectional comparison of an automated hybrid capture 2 assay and
the consensus GP5+/6+ PCR method in a population-based cervical
screening program. J Clin Microbiol 2006, 44(10):3680–3685.
21. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras
C, Silva S, Gonzalez P, Bratti MC, et al: Comparison of the SPF10-LiPA
Halfon et al. BMC Infectious Diseases 2013, 13:499 Page 5 of 6
http://www.biomedcentral.com/1471-2334/13/499
system to the Hybrid Capture 2 Assay for detection of carcinogenic
human papillomavirus genotypes among 5,683 young women in
Guanacaste. Costa Rica. J Clin Microbiol 2007, 45(5):1447–1454.
22. Sandri MT, Lentati P, Benini E, Dell’Orto P, Zorzino L, Carozzi FM,
Maisonneuve P, Passerini R, Salvatici M, Casadio C, et al: Comparison of the
Digene HC2 assay and the Roche AMPLICOR human papillomavirus
(HPV) test for detection of high-risk HPV genotypes in cervical samples.
J Clin Microbiol 2006, 44(6):2141–2146.
23. Stevens MP, Garland SM, Tabrizi SN: Development and validation of a
real-time PCR assay specifically detecting human papillomavirus 52 using
the Roche LightCycler 480 system. J Virol Methods 2008, 147(2):290–296.
doi:10.1186/1471-2334-13-499
Cite this article as: Halfon et al.: Comparison of the performance of
carcinogenic HPV typing of the Roche Linear Array and Qiagen
LiquiChip® HPV assays. BMC Infectious Diseases 2013 13:499.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Halfon et al. BMC Infectious Diseases 2013, 13:499 Page 6 of 6
http://www.biomedcentral.com/1471-2334/13/499
